Valor202020212022202320242025TTMGastos comerciales, generales y administrativos50.8 M63.3 M75.5 M72.74 M75.95 M97.16 M97.16 MInvestigación y desarrollo9.2 M7.92 M9.34 M9.52 M12.77 M6.58 M6.58 MBeneficio operativo-22.31 M-27.56 M-35.11 M-30.55 M-34.56 M-31.44 M-31.44 MTotal de ingresos no operativos302 K390 K2.2 M5.79 M2.55 M716 K716 KGastos por intereses, netos de intereses capitalizados4.52 M4.02 M4.25 M5.42 M7.29 M16.82 M8.2 MIngresos no operativos, una vez deducidos los gastos por intereses-4.52 M-4.02 M-4.25 M-5.42 M-7.29 M-16.82 M-8.2 MIngresos/gastos extraordinarios302 K390 K2.2 M5.79 M2.55 M716 K716 KBeneficio antes de impuestos-26.83 M-30.47 M-36.51 M-29.57 M-42.94 M-39.13 M-38.32 MParticipación en los beneficios———————Impuestos000-7.7 M00—Participación minoritaria————-19 K-137 K-137 KOtros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-27.45 M-31.19 M-37.16 M-30.19 M-43.71 M-39 M-39 MOperaciones suspendidas———————Beneficio neto-27.45 M-31.19 M-37.16 M-30.19 M-43.71 M-39 M-39 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-27.45 M-31.19 M-37.16 M-30.19 M-43.71 M-39 M-39 MBeneficio básico por acción—-1.22-1.38-1.05-1.38-0.59-0.59Beneficio por acción diluido—-1.22-1.38-1.05-1.38-0.59-0.59Número medio de acciones ordinarias—25.48 M26.9 M28.66 M31.73 M65.95 M260.9 MAcciones diluidas—25.48 M26.9 M28.66 M31.73 M65.95 M260.9 MEBITDA-25.87 M-30.5 M-37.76 M-33.95 M-39.79 M-36.37 M-36.37 MEBIT-26.81 M-31.56 M-39.41 M-35.95 M-41.86 M-39.84 M-39.84 MCosto de los ingresos11.55 M11.65 M15.48 M19.64 M20.73 M76.85 M76.85 MOtros costes de producción———1.91 M626 K388 K388 KAmortización y depreciación (flujo de caja)941 K1.06 M1.65 M2.01 M2.07 M3.46 M3.46 M
Neuronetics Inc
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
Neuronetics became the "first and only Food and Drug Administration approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device."
They manufacture a transcranial magnetic stimulation device, NeuroStar. The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.